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ABSTRACT 
Objective: The objective of the present investigation was to the development of floating pulsatile drug delivery system of Losartan potassium (LP) 
tablets for obtaining no drug release during floating followed by pulsed, rapid drug release to achieve chronotherapeutic release. In hypertension, 
the risk of getting heart attacks early in the morning is high and therefore, there was need to develop drug delivery, which will release drugs at 
morning hours and provide efficacious therapy. LP is a short biological half-life (1.5-2.5h) and readily absorbed from the stomach and upper 
gastrointestinal tract.  
Methods: Tablet formulation was prepared by press coating of rapid release core tablets and core tablets were further top coated with a buoyant 
layer of HPMC K4M and sodium bicarbonate. Various grades of HPMC polymer (E5/E15/E50) were used for the pulsatile coating layer. The 
developed formulations were characterized for physical characteristics, floating lag time, floating time, release lag time, drug content, swelling 
index, in vitro dissolution studies, DSC and XRD.  
Results: The FTIR and DSC studies predicted that there was no chemical interaction between drug and excipients. The core tablet coated with 
HPMC E50 showed a high swelling index and release the drug 97.60±1.2% at 6h. Buoyant layer with 80 mg HPMC K4M and 25 mg sodium 
bicarbonate gave satisfactory floating lag time.  
Conclusion: The system showed an excellent lag phase followed by burst release in the distal small intestine, which gives site and time-specific 
delivery of LP acting as per chronotherapy for treatment of hypertension.  
Keywords: Losartan potassium, Floating, Pulsatile, Circadian rhythm, Press coating 
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INTRODUCTION 
Chronopharmaceutics, the drug delivery based on circadian rhythm, 
is recently gaining much attention worldwide. Various diseases like 
asthma, hypertension, and arthritis show circadian variation, which 
demands time scheduled drug release for effective drug action. To 
follow this principle, one must have to design the dosage form so 
that it can be given at a convenient time, e. g. bedtime for 
hypertension with the drug release in the morning would be a 
promising chronotherapeutic system. For this, a pulsatile release 
profile, where the drug is released completely after a defined lag 
time, is advantageous. A combination of floating and pulsatile 
principles of drug delivery system would have the advantage that a 
drug can be released in the distal small intestine after a defined time 
period of no drug release [1].  
The gastroretentive floating pulsatile drug delivery system 
(GRFPDDS) is useful for those drugs, which have dependent pH 
solubility, poor bioavailability in the gastrointestinal tract (GIT) and 
narrow absorption window. Gastro retentive systems (GRS) can 
remained in the gastric region for several hours and hence 
significantly prolong the gastric residence time of drugs. Prolonged 
gastric retention improves bioavailability, reduces drug waste and 
improves the solubility of drugs that are less soluble in high pH 
environments [2, 3]. 
Different approaches used for gastroprotection and to enhance the 
bioavailability of drugs such as floating drug delivery systems 
(FDDS), bioadhesive or mucoadhesive systems, swelling and 
expandable systems, high-density systems, raft systems, ion 
exchange resins, controlled osmotic systems etc. Floating pulsatile 
dosage forms, which are retained in the stomach for a long time (4-
12 h) and not affected by variation in gastric pH, local environment 
or gastric emptying rate. These dosage forms may be either single 
unit (floating tablets) or multi particulates (beads, pellets, granules, 
microspheres) with the capability of gastro-retention. These 
systems are specifically beneficial for drugs, either absorbed from 
the stomach or requiring local delivery in the stomach [4]. 
It is well established that many of the body functions display 
circadian rhythms e. g. in peptic ulcer, the acid secretion is high in 
the afternoon and night, in case of asthma, precipitation of symptom 
during the night and early morning is high. Similarly, in 
cardiovascular disease, blood pressure is at its lowest during the 
sleep cycle and rises steeply during the early morning awaking 
period and in arthritis, the pain is more in the early morning. LP is 
an angiotensin II receptor antagonist used in the treatment of 
hypertension. The bioavailability of about 33% and plasma half-life 
ranging from 1.5 to 2.5 h. The other disorders that follow circadian 
rhythm are diabetic mellitus, angina pectoris, and rheumatic 
diseases [5]. Controlled releases that display a pulse release are 
mainly prepared by polymeric materials and systems that are made 
up of a reservoir and covered with a barrier. This barrier can be 
dissolved or eroded after which the drug is released. The release 
from such formulation can be modified to get a single pulse, double 
pulse, and multi-pulse release pattern [6]. 
The aim of the present work was to the development of a pulsatile 
drug release system of LP for the effective treatment of 
hypertension. LP is an angiotensin-II receptor antagonist drug which 
is mainly used to treat high blood pressure and it well absorbed 
after oral administration.  
MATERIALS AND METHODS 
Losartan Potassium was obtained as a gift sample from Macleod’s 
Pharmaceuticals Mumbai, Microcrystalline cellulose, HPMC, sodium 
bicarbonate were purchased from Loba Chem. Pvt. Ltd. Mumbai, 
Lactose, Sodium starch glycolate, Cross povidone, Polyvinyl 
Pyrrolidone, magnesium stearate were purchased from Molychem 
Mumbai. All other reagents and chemicals used were analytical 
grade. 
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The sample of LP was characterized for its physical state, colour and 
odour. The melting point was determined using a capillary tube 
method. Solubility study was carried out using different solvents. 
Fourier transforms infrared (FTIR) spectroscopy studies were used 
for the evaluation of physicochemical compatibility and interactions 
among drugs and excipients.  
Preparation of rapid release core tablets (RRCT)  
Core tablet was formulated by using various concentrations and 
different types of diluents and superdisintegrants. The drug, diluent, 
superdisintegrant and binder were weighed as per formulae given in 
[table 1]; these were then passed through sieve no.20 transferred to 
a polybag and blended for 5 min. To the homogeneous blend with 
magnesium stearate for 2 min. The resulting blend was compressed 
by using a rotary tablet compression machine to get a tablet of 110 
mg weight with a diameter of 8 mm [7]. 
 
Table 1: Composition of the core tablet of losartan potassium 
Name of ingredients Batches (mg) 
CT-1 CT-2 CT-3 CT-4 CT-5 CT-6 
Losartan potassium 50 50 50 50 50 50 
Microcrystalline cellulose 46.8 29 21.8 46.8 29 21.8 
Lactose 10 20 25 10 20 25 
Sodium starch glycolate 6.6 8.8 11 - - - 
Cross povidone - - - 6.6 8.8 11 
PVP K-30 1.1 1.1 1.1 1.1 1.1 1.1 
Magnesium stearate 1.1 1.1 1.1 1.1 1.1 1.1 
Total weight of tablet 110 110 110 110 110 110 
 
Preparation of the pulsatile release tablets (PRTs) 
The optimized pulsatile release tablets were prepared by using 
different grades of HPMC (E5, E15 and E50) at different 
concentrations given in [table 2]. Dry coated tablet was prepared by 
placing 50% of pulsatile release layer in 10 mm die and rapid 
release core tablet (RRCT) layer was placed on it and then remaining 
quantity of pulsatile release layer was added in the cavity, so as to 
cover the RRCT and finally compressed using rotary tablet 
compression machine [8]. 
 
Table 2: Composition of PRTs batches 
Polymer used Conc. in mg/tablet 
HPMC E5  200 220 240 260 280 300 
HPMC E15  200 220 240 260 280 300 
HPMC E50  200 220 240 260 280 300 
 
Preparation of floating pulsatile release tablets (FPRTs) 
A 32randomized full factorial design was used to optimize the 
composition of the buoyant layer. In the design two factors were 
evaluated, each at three levels and experimental trials were 
performed at all 9 possible combinations. The concentrations of 
HPMC K4M (X1) and sodium bicarbonate (X2) were selected as 
independent variables. All the nine possible combinations of 
buoyant powder were filled into the die individually, followed by the 
addition of optimized PRT and finally, compression was done. The 
optimized concentrations of HPMCK4M and sodium bicarbonate 
were incorporated in the floating tablet, which was used as the 
checkpoint of the regression analysis model. The 32
Optimization of formulation using factorial design 
 factorial designs 
for floating pulsatile tablet reported in [table 3]. The independent 
variables with their actual values were shown in [table 4].  
A statistical model incorporating interactive and polynomial term 
was used to evaluate the responses. 
Y =  β0 + β1X1 + β2X2 + β12 X1X2 + β11X1X1 + β22X2X2 … . Eq. 1 
Where Y is the dependent variable, β0 is the arithmetic mean response 
of the nine runs, and b1 is the estimated coefficient for the factor x1. 
The main effects (x1, x2) represent the average result of changing one 
factor at a time from its low to high value. The interaction terms (x1, x2) 
showed how the response changes when two factors are changed 
simultaneously. The polynomial terms (x1, x2) are included to 
investigate nonlinearity. From the data of floating lag time parameters 
for factorial composition F1 to F9 polynomial equation for the 
dependent variable has been derived. In this equation, the negative 
sign indicates a negative correlation and the positive sign indicates a 
positive correlation to the independent variables X1 and X2 [9, 10]. 
Evaluation of RRCTs 
Thickness and diameter are important parameters in the evaluation 
of tablet as it ensures uniformity of tablet size. The thickness of the 
tablet was determined using a Vernier caliper. Three tablets from 
formulation were used to measure thickness and diameter and 
average values were recorded in mm. For each formulation, the 
hardness of tablets was determined using the Monsanto hardness 





 Factorial designs for floating tablet 
code 
Independent variables 
HPMC K4M (X1)  Sodium bicarbonate (X2) 
F1 -1 -1 
F2 -1 0 
F3 -1 +1 
F4 0 -1 
F5 0 0 
F6 0 +1 
F7 +1 -1 
F8 +1 0 
F9 +1 +1 
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Table 4: Independent variables with their actual values 
Independent variables Low (-1) Medium (0) High (+1) 
X1 (HPMC K4M in mg) 60 70 80 
X2 (Sodium bicarbonate in mg) 15 20 25 
  
Weight variation test 
20 tablets were selected randomly, weighed individually and the 
average weight of tablet was determined. Individual tablet weight was 
then compared with the average value to find the deviation in weight. 
The weight variation for each tablet was determined using formula 1, 
% weight variation =
(Individual weight− average weight) 
 (Average weight)
 
× 100 … .1 
Tablet passes the test if not more than two tablet falls outside 
permitted limit and in no case, any tablet shows variation equal to or 
greater than twice of permitted limit as per standard.  
Drug content 
The content uniformity test was carried out to ensure content of LP 
in each tablet i.e. to ensure dose uniformity. Ten tablets were 
weighed and calculate average weight and crushed in to powder in 
mortar-pestle. Powder triturate equivalent to 50 mg of LP was 
dissolved in 100 ml 0.1N HCL. Solution was filtered through 
whatmann filter paper no. 42 and 1 ml of the filtrate was diluted to 
the 10 ml with 0.1N HCL [12]. Absorbance of the resultant solution 
was measured using UV-Visible spectrophotometer at 205 nm 
wavelength. Content uniformity was calculated using formula 2, 
% Purity =  10 C
(Au) 
 (As)
 … .2 
Where, C: Concentration, Au and As: Absorbance’s obtained from 
standard preparation and assay preparation. 
In vitro disintegration time 
The disintegration test was carried out using USP in vitro 
disintegration test apparatus. Tablets were placed in each of the six 
tubes of the basket, contacting water maintained temperature at 37 
°C±2 °C as per specified in the individual monograph. The time taken 
by the tablet for complete disintegration, leaving no tablet residue 
on wire screen, was recorded. 
In vitro dissolution studies 
The release rate of LP from rapid release core tablet was determined 
using USP dissolution testing apparatus II. The dissolution test was 
performed using 900 ml of 0.1N HCL at 37±0.5 °C and rotation 50 
rpm, a sample volume of 5 ml was withdrawn at regular time 
intervals. The volume withdrawn was replaced by a fresh volume of 
dissolution medium to maintain sink condition. The filtered samples 
were analyzed spectrophotometrically at 205 nm wavelength. Drug 
content in the dissolution sample was determined [13]. 
Evaluation of pulsatile release tablets 
Pulsatile release tablets were evaluated for parameters like 
diameter, thickness, hardness, uniformity of weight, in vitro drug 
release as per the procedure mentioned for evaluation of core tablet. 
Swelling index 
The swelling properties of tablets were determined by placing the 
tablets in the dissolution test apparatus, in 900 ml of 0.1 N HCL at 
37±0.5 °C. The tablets were removed periodically from the 
dissolution medium, blotted to remove an excess of water and 
weighed [14]. Swelling characteristics were expressed in terms of 
percentage of water uptake (WU %), calculated by formula 3. 
%Water uptake =
Weight of swollen tablet– Initial weight of tablet 
 Weight of tablet
 
× 100 … . 3 
In vitro dissolution studies 
The release rate of LP from pulsatile release tablets was determined 
using USP dissolution testing apparatus II (TDT 08L Electrolab 
Mumbai, Maharashtra, India). The dissolution study was performed 
using the same procedure for core tablet [15, 16]. 
Evaluation of floating-pulsatile release tablet (FPRT) 
FPRT was evaluated for parameters like diameter, thickness, 
hardness, uniformity of weight, in vitro drug release as per the 
procedure mentioned for evaluation of core tablets. 
In vitro buoyancy studies 
The in vitro buoyancy test was conducted by placing the tablet in 900 ml 
0.1N HCL maintained pH 1.2, 37±0.5 °C temperature and speed of 
rotation at 50 rpm. The time is taken by tablet to float on surface after its 
introduction in the medium (floating lag time) and entire duration, 
during tablet remained float on the surface of the medium (total floating 
time) were recorded by visual observation [17, 18]. 
Fourier transform infrared spectroscopy study (FTIR) 
FTIR absorption spectrum of TA was determined by fourier 
transform infrared spectrophotometer FTIR (Jasco 4100, Shimadzu, 
Japan). Briefly, about 2 mg of sample was ground thoroughly with 
previously dried KBr at 120 °C for 30 min; uniformly mixed with 
drug sample and kept in the sample holder, spectra were recorded 
over the wavenumber 400-4000 cm-1
Powder X-ray diffractometry (PXRD) 
. Infrared spectrums of pure 
drug and optimized batches were recorded.  
PXRD studies were carried out in order to study any change in the 
crystalline nature of the pure drug and optimized formulation [19, 
20]. Study of crystallinity of solids by using Bragg’s equation 2, 
nλ =  2 d sin θ … . Eq. 2 
Where, 
n = is an order of diffraction 
λ = wavelength of X-rays 
d = Spacing distance between two planes of crystal 
θ = Angle of diffraction  
Differential scanning calorimetric (DSC) study 
DSC studies provide qualitative and quantitative information about 
physical and chemical changes of a compound that involve endothermic 
and exothermic processes, or changes in heat capacity. Thermograms of 
LP and optimized formulation were obtained using DSC instrument (TA 
Instruments SDT-2960, USA) equipped with an intra-cooler. Indium 
standard was used to calibrate the DSC temperature and enthalpy scale. 
The powder samples of the formulation was kept in the aluminum pan 
and heated at a constant rate 50 °C/min, over a temperature range of 
100 °C to 300 °C. Inert atmosphere was maintained by purging nitrogen 
at the flow rate of 100 ml/min [21, 22]. 
Stability studies 
The stability studies were carried out according to (ICH) Q1A (R2) 
guidelines (FDA, 2003). The optimized formulation was subjected to 
accelerated stability studies at 40±2 °C/75±5% RH for a period of 2 mo 
in stability chamber. Tablets were packed in amber-colored wide mouth 
glass bottle hermetically sealed. The samples were taken out at 30 and 
60 d and evaluated for the physical parameters, % drug content, in vitro 
% drug release study, floating lag time and floating time [23]. 
RESULTS AND DISCUSSION 
Preformulation studies 
The sample of LP was found to be white to off white crystalline 
powder having a bitter taste. Melting point of LP was found to be in 
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the range of 263-265 °C. LP was found to be soluble in water, 
methanol, ethanol and acetonitrile. The FTIR spectrum of LP exhibits 
a characteristic peak at 760 cm-1,1000 cm-1, 1462 cm-1, 1575 cm-1 
and 2995 cm-1
Evaluation of powder blends 
 due to chloride moiety, secondary hydroxyl group, 
aromatic ring, nitrogen moiety and an aliphatic chain respectively.  
The powder blend of all the formulations batches (1-6) were 
subjected for various pre-compressional evaluation parameters such 
as angle of repose, bulk and tapped density, compressibility index 
and Hausner's ratio. Results of all the pre-compression parameters 
performed of the blends for all batches shown in [table 5]. The 
prepared powder blends were within the limit of all specified values 
and showed good powder characteristics. Angle of repose was found 
to be in the range of 23.48° to 29.78°. The powder blends of all 
formulations showed good flow property. The bulk density and 
tapped density of blends were found to be in the range of 0.4647 to 
0.4852 g/cm3 and 0.5076 to 0.55 g/cm3,
 
 respectively. This indicates 
a good packing capacity of blends. Carr’s index was calculated and 
the results were shown in [table 5]. It was found to be in the range of 
5.79 to 14.54 indicates that, the powder blend has required flow 
property. Values of Carr’s index below 15% usually show good flow 
characteristics. Hausner’s ratio of all formulations was found to be 
1.06 to 1.17 indicates the good flow properties of blends. 
Table 5: Flow properties of a powder blend 
Batch codes Bulk density (g/cm3 Tapped density (g/cm) 3 Angle of repose (θ) ) Carr’s index (%) Hausner’s ratio 
1 0.4782±0.002 0.5076±0.003 25.07±0.22 5.79±0.01 1.06±0.006 
2 0.4714±0.003 0.5409±0.004 25.07±0.21 12.00±0.22 1.14±0.005 
3 0.4852±0.001 0.5500±0.003 23.48±0.32 14.06±0.18 1.13±0.006 
4 0.4714±0.002 0.5500±0.001 26.82±0.14 14.54±0.34 1.17±0.003 
5 0.4852±0.004 0.5409±0.002 29.78±0.21 10.31±0.59 1.14±0.008 




Evaluation of RRCTs 
The result indicates that, the mean diameter and thickness of core 
tablets (n=3) were found to be within the range of 8.04 to 8.07 mm 
and 1.61 to 1.64 mm respectively. Hardness of core tablets was 
found to be between 2.81 to 2.9 kg/cm2
 
. The hardness of all the 
formulations was almost uniform and the tablets possess good 
mechanical strength. The percentage weight variations for all tablets 
were passed test as all the values within range as per the standard 
limits. The disintegration time of tablets were found to be between 
134 to 513s. From the results, it was observed that tablets 
formulation (CT-6) containing higher concentration of 
superdisintegrant cross povidone showed rapid disintegration as 
compared to the formulation (CT-3) containing sodium starch 
glycolate. In the assay of all the formulation, the tablets of all batches 
showed 96.39±0.58 to 98.96±0.06 % of drug content, respectively. 
The results were within the limit (90% to 110%) specified in the 
pharmacopoeia. The results of diameter, thickness, hardness, weight 
variation test, in vitro disintegration test and drug content were 
shown in [table 6]. 
Table 6: Evaluation of RRCT 
Batch 
codes 






Drug content (%) 
CT-1 8.05±0.02 1.61±0.01 2.9±0.10 109.9±0.73 513 97.57±0.11 
CT-2 8.07±0.01 1.62±0.01 2.9±0.20 109.8±0.63 460 98.73±0.20 
CT-3 8.06±0.02 1.62±0.01 2.81±0.01 110.0±0.21 406 96.39±0.58 
CT-4 8.06±0.01 1.64±0.02 2.84±0.04 109.7±0.48 253 96.45±0.62 
CT-5 8.06±0.01 1.63±0.01 3.00±0.10 109.9±0.32 190 97.64±0.08 




Fig. 1: % Drug release of RRCTs (mean±SD; n=3) 
 
In vitro dissolution studies 
In vitro drug release studies reveals that, formulations containing cross 
povidone (CT4-CT6) showed fast dissolution than the sodium starch 
glycolate. Dissolution of LP RRCTs increases with an increase in the 
concentration of sodium starch glycolate and cross povidone due to 
rapid swelling and disintegration. The tablets prepared with cross 
povidone have maximum drug release as these tablets have less 
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disintegration time owing to the formation of larger pores with 
continuous network in dissolution media and swelling provide enough 
pressure for faster disintegration, additionally, it also have the capability 
to swell at least twice of its original volume, when contact with 
dissolution fluid.  
Among six formulations of LP inner core tablets, it was observed 
that, when cross povidone used in a concentration of 10 % provides 
rapid disintegration and maximum dissolution rate. Latha K et al. 
reported that, Hydroxypropyl methylcellulose (HPMC) forms a firm 
gel but does not hydrate quickly while MCC is a good disintegrant 
and acts by a wicking mechanism. Hence, the drug was immediately 
released from the tablet core after the rupture of the surrounding 
outer layer containing MCC alone and admixture of HPMC100KM 
and MCC [7]. In vitro drug release profiles for all the batches of 
RRCTs of LP are given in [fig. 1]. 
Evaluation of pulsatile release tablets 
All the tablets formulations were subjected for evaluation of 
parameters like shape, thickness, diameter, hardness, release lag 
time, in vitro dissolution studies. The result indicates that, the mean 
thickness and diameter of PRTs (n=3) were found to be within the 
range of 2.93 to 4.23 mm and 10.04 to 10.07 mm respectively. 
Hardness of PRTs was found to be between 4.60 to 4.80 kg/cm2
Formulations containing HPMC E5, E15 and E50 showed increasing 
order of lag time with the respective increase in polymer 
concentration from 200-300 mg depending on their individual 
viscosity grades. The results of thickness, diameter, hardness and lag 
time of PRTs are shown in [table 7]. All the batches of PRTs showed 
a difference in their dissolution profiles with respect to lag time 
depending on viscosity grade and concentration of polymer used for 
the coating of core tablet. Jagdale SC et al. revealed that, as the PRTs 
of different batches placed in dissolution medium hydrophilic 
polymeric coat start to erode but it erode up to a limited thickness of 
tablet as swelling of core tablet because of swelling of disintegrant 
present in core tablet on contact with dissolution medium result in 
increased internal pressure and subsequent rupture of polymer 
coating takes place owing to burst release of the drug. All the batches 
of PRTs were compared for their physical parameters and drug release 
profiles with respect to lag time. From the results, it was indicated that 
PRT coated with 300 mg of the polymer showed maximum release lag 
time with respect to the ascending order of their viscosity grades 
(E5<E15<E50). PRTS coated with 300 mg of E5, E15, E50 showed 59.54, 
63.74 and 63.37 % drug release after lag time of 165, 270, 390 min, 
respectively. Even though PRTs coated with HPMC E50 300 mg showed 
lag time of 390 min PRT coated with 280 mg of HPMC E50 selected for 
treatment of hypertension as it shows the suitable lag time of 360 min 
and 97.60 % drug release. Shivhare et al. reported that the ratio of 
polymer Eudragit increased, there was an increased lag time and 
decrease in drug release rate. This could cause a decrease in the effective 
diffusion coefficient of the drug. [25] The results of in vitro drug release 
of PRTs was shown in [fig. 2,3 and 4]. 
. The 
hardness of all the formulations was almost uniform and the tablets 
possess good mechanical strength. From the results, it was revealed 
that lag time goes on increasing with increasing viscosity grades of 
HPMC polymer and concentration of polymer. Bajpai et al. reported 
that coating with carboxymethyl cellulose sodium showed the least 
lag time because of its high permeation and high water-absorbing 
character, which leads to quick hydration of core tablet that evolves 
gas generating internal pressure. Also, carboxymethyl cellulose 
sodium has a lower extent of cross-linking and gelling character than 
other three polymers that provided a lesser extent of mechanical 
strength to its coat [24]. 
 
Table 7: Evaluation of PRTs 
Batch codes Thickness (mm) Diameter (mm) Hardness (Kg/cm2 Lag time (min) ) 
PRT-E5200  2.93±0.002 10.06±0.01 4.7±0.10 30 
PRT-E5220  3.28±0.01 10.07±0.01 4.6±0.20 60 
PRT-E5240  3.44±0.01 10.05±0.02 4.7±0.20 90 
PRT-E5260  3.72±0.005 10.04±0.01 4.6±0.10 135 
PRT-E5280  4.06±0.01 10.06±0.01 4.7±0.20 150 
PRT-E5300  4.23±0.01 10.06±0.01 4.6±0.10 165 
PRT-E15200  2.99±0.02 10.05±0.02 4.6±0.23 120 
PRT-E15220  3.23±0.01 10.06±0.02 4.6±0.10 135 
PRT-E15240  3.42±0.11 10.06±0.01 4.7±0.20 180 
PRT-E15260  3.76±0.15 10.06±0.011 4.6±0.10 195 
PRT-E15280  4.03±0.02 10.04±0.01 4.7±0.10 255 
PRT-E15300  4.26±0.02 10.06±0.02 4.6±0.10 270 
PRT-E50200  2.97±0.02 10.07±0.01 4.7±0.20 255 
PRT-E50220  3.23±0.01 10.06±0.01 4.6±0.10 285 
PRT-E50240  3.42±0.02 10.06±0.02 4.63±0.11 315 
PRT-E50260  3.74±0.001 10.05±0.01 4.7±0.15 345 
PRT-E50280  4.03±0.01 10.04±0.01 4.8±0.20 360 
PRT-E50300  4.30±0.02 10.05±0.02 4.7±0.2 390 
* mean±(SD) n=3 
 
 
Fig. 2: % drug release of PRTs coated with HPMC E5 (200-300) (mean±SD; n=3) 
Shinde et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 218-227 
223 
 
Fig. 3: % drug release of PRTs coated with HPMC E15 (200-300) (mean±SD; n=3) 
 
 
Fig. 4: % drug release of PRTs coated with HPMC E50 (200-300) (mean±SD; n=3) 
 
Swelling index 
The swelling behavior of optimized PRT containing HPMC E50 was 
compared with other PRTs containing HPMC E5 and HPMC E15 at 
the same concentration i.e. 280 mg. The results indicated that the 
swelling front erodes faster for PRTs coated with HPMC E5 as 
compare to PRTs coated with HPMC E15 and E50 due to their 
marked viscosity properties shown in [fig. 5]. The thickness of the 
swelled layer of PRT coated with HPMC E50 was higher as 
compared with PRTs with HPMC E5 and HPMC E15. This was due 
to the complete penetration of the solvent and high viscosity of the 
HPMC E50. Raghavendra et al. reported that the ethylcellulose 
showed highest lag time, which is based upon the hydration of 
outer barrier layer or water penetration through the outer barrier 
layer. The formulated bilayered tablets achieved a burst release 
after 3-4 h lag time [26].  
Dhakar VK et al. showed that the direct correlation between swelling 
and lag time was observed and found that the formulations having 
maximum swelling indices showed the higher lag time. 
 
 
Fig.5: Swelling indices of PRT coated with HPMC E5/E15/E50 (280 mg) (mean±SD; n=3) 
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Evaluation of floating-pulsatile release tablet (FPRT) 
In vitro Buoyancy studies 
HPMC was a hydrophilic swellable polymer used in controlled 
release swellable hydrophilic matrices. Reddy et al. reported that, 
sodium bicarbonate was used as a gas generating agent and this 
compound generates carbon dioxide on the reaction with acidic 
aqueous media, which get entrapped into the hydrocolloid gel layer 
of tablet and due to gas entrapment tablet become buoyant. The 
equation derived for floating lag time was:  
Y =  8.7377 − 1.3283 X1 − 2.8950 X2 + 3.76 X1X2 … . Eq. 3 
The β0= 8.73, which is the arithmetic mean of all nine batches. The 
negative coefficient of X1 indicates that as the concentration of X1 
(HPMC K4M) increases; there is a decrease in the floating lag time of 
tablets. The negative coefficient of X2 indicates that as the 
concentration of X2 (sodium bicarbonate) increases, the floating lag 
time of tablet was decreased. 32
Fourier transform infrared spectroscopy studies 
 full factorial designs with observed 
responses shown in [table 8]. The surface response curve shown in 
[fig. 6]. 
The FTIR spectrum of formulation F9 shows a broad peak at 
3753.23 cm-1, indicating the presence of the primary alcoholic OH 
group. A peak is shown at 1542 cm-1 and 775.19 cm-1, depicting 
nitrogen and chloride moiety. One sharp peak of aryl chloride was 
observed at 1117 cm-1
 
. In comparison with the pure drug, the 
absorption peak of the spectra for LP in FPDDS form optimized 
formulation batch F9 showed no significant shift of characteristic 
peaks suggesting that there is no interaction between drug and 
excipients. IR spectra of LP, physical mixture and optimized 
formulation batch F9 as shown in [fig. 7-9]. 
Table 8: Coded level as per 32
Batch codes 
 full factorial designs with observed responses 
X1 X2 Floating lag time (min) Floating time (in h) 
F1 -1 -1 19:21 >12 
F2 -1 0 10:04 >12 
F3 -1 +1 8:56 >12 
F4 0 -1 11:37 >12 
F5 0 0 9:15 >12 
F6 0 +1 7:23 >12 
F7 +1 -1 5:25 >12 
F8 +1 0 5:16 >12 
F9 +1 +1 5:06 >12 
 
 
Fig. 6: Response surface plot showing the effect of factorial variables on floating lag time and floating time 
 
 
Fig. 7: IR spectra of losartan potassium 
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Fig. 8: IR spectra of the physical mixture of batch CT-6 
 
 
Fig. 9: IR spectra of optimized batch F9 
 
Powder X-ray diffractometry studies 
PX-RD spectra indicated that the sharp peaks were seen in the PXRD 
spectra of the pure drug indicates crystalline nature of drug while 
optimized formulation (F9) has shown the peaks with reduced 
intensities denoting reduced crystallinity of drug. The overlay of PX-
RD pattern of pure drug and optimized formulation (F9) was shown 
in [fig. 10]. 
  
 
Fig. 10: Overlay PX-RD spectra of pure drug (a) and optimized batch F9 (b) 
 
Differential scanning calorimetry studies 
DSC studies were conducted for the study of physical state of the 
drug in the formulation. In the thermogram of pure drug, sharp 
endotherm was obtained at near about 260.91°C, which shows the 
melting point of the drug. The LP has shown an endothermic peak at 
260.91 °C. The peak was shifted in the case of DSC of the LP 
optimized batch formulation. The DSC of the tablet triturate of FPRT 
of LP showed an endothermic peak at 199.49 °C. The results reveals 
that there was a reduction in crystallinity in the polymer matrix and 
no incompatibility between drug and other excipients.  
The thermograms of LP and optimized batch (F9) shown in [fig. 11 
and 12]. 
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Fig. 11: DSC thermogram of losartan potassium 
 
 
Fig. 12: DSC thermogram optimized batch F9 
 
Stability studies 
Short term stability study was performed for formulation CT-6 at 
40±2.0 °C and RH 75%±5% for two months. The samples were 
analyzed for diameter, thickness, weight variation, hardness, 
disintegration time, percent drug content and in vitro drug release 
studies. The results of all parameters indicated that no significant 
difference in parameters observed before and after stability studies 
shows in [table 9]. Short term stability studies of FPRTs were 
performed of the optimized formulation F9, indicated that there was 
no significant difference in physical parameters, floating lag time 
and floating time shown in [table 10]. 
 
Table 9: Evaluation parameters of optimized core tablet (CT-6) 
Parameters Before After 
Diameter (mm) 8.04±0.01 8.03±0.01 
Thickness (mm) 1.64±0.005 1.64±0.01 
Weight variation (%) 110.0±0.47 109.9±0.6 
Hardness ((kg/cm2 2.90±0.06 ) 3.00±0.02 
Disintegration time (s) 134±0.02 135±0.02 
Drug content (%) 98.96±0.06 98.35±0.01 




Table10: Evaluation of FPRTs 
Parameters Before After 
Diameter (mm) 10.04±0.002 10.06±0.004 
Thickness (mm) 4.8±0.002 4.7±0.004 
Floating lag time (min) 5.06±0.02 6.32±0.01 





The FPDDS was developed successfully using press coating 
technique. The present investigation revealed that the coating of 
core tablet with 280 mg of HPMC E50 and top coating of PRT with 
floating layer containing 80 mg HPMC K4M and 25 mg sodium 
bicarbonate provided desired lag time required for chronotherapy of 
hypertension. The optimized formulation showed 6 h of pulsatile 
Shinde et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 218-227 
227 
release lag time, 5 min floating lag time and greater than 12 h of 
floating time. In vitro drug release study showed 97.60 % drug 
release in 0.1N HCL within 30 min, indicating burst release. 
Optimized formulation (F9) showed good stability at accelerated 
stability conditions. From the experimental findings it can be 
concluded that floating pulsatile tablets of Losartan potassium can 
give efficient therapy by reducing dose and dosing frequency and 
provide chronotherapy for an effective management of morning 
surge of hypertension. Finally, it may be concluded that floating 
pulsatile drug delivery system offers a valuable dosage form 
treatment of hypertension.  
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